FI963805A0 - Hermotukisoluista peräisin olevaa neurotrofista tekijää (GDNF) koodaavat yhdistelmä-DNA-tekniset adenovirukset - Google Patents
Hermotukisoluista peräisin olevaa neurotrofista tekijää (GDNF) koodaavat yhdistelmä-DNA-tekniset adenoviruksetInfo
- Publication number
- FI963805A0 FI963805A0 FI963805A FI963805A FI963805A0 FI 963805 A0 FI963805 A0 FI 963805A0 FI 963805 A FI963805 A FI 963805A FI 963805 A FI963805 A FI 963805A FI 963805 A0 FI963805 A0 FI 963805A0
- Authority
- FI
- Finland
- Prior art keywords
- gdnf
- recombinant adenoviruses
- adenovirus
- cell
- dna sequence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9403542A FR2717824B1 (fr) | 1994-03-25 | 1994-03-25 | Virus recombinants, préparation et utilisation en thérapie génique. |
PCT/FR1995/000356 WO1995026408A1 (fr) | 1994-03-25 | 1995-03-23 | Adenovirus recombinants codant pour le facteur neurotrophique des cellules gliales (gdnf) |
Publications (2)
Publication Number | Publication Date |
---|---|
FI963805A0 true FI963805A0 (fi) | 1996-09-24 |
FI963805A FI963805A (fi) | 1996-09-24 |
Family
ID=9461438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI963805A FI963805A (fi) | 1994-03-25 | 1996-09-24 | Hermotukisoluista peräisin olevaa neurotrofista tekijää (GDNF) koodaavat yhdistelmä-DNA-tekniset adenovirukset |
Country Status (14)
Country | Link |
---|---|
US (1) | US6245330B1 (fi) |
EP (1) | EP0752004B1 (fi) |
JP (1) | JPH09510620A (fi) |
KR (1) | KR100403707B1 (fi) |
AT (1) | ATE335832T1 (fi) |
AU (1) | AU704910B2 (fi) |
CA (1) | CA2184841C (fi) |
DE (1) | DE69535155T2 (fi) |
FI (1) | FI963805A (fi) |
FR (1) | FR2717824B1 (fi) |
IL (1) | IL113109A0 (fi) |
MX (1) | MX9604024A (fi) |
WO (1) | WO1995026408A1 (fi) |
ZA (1) | ZA952433B (fi) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE404683T1 (de) * | 1992-09-25 | 2008-08-15 | Aventis Pharma Sa | Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn |
US20020031493A1 (en) * | 1994-03-25 | 2002-03-14 | Rhone-Poulenc Rorer S.A. | Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf) |
US5733875A (en) * | 1994-11-15 | 1998-03-31 | Amgen Inc. | Methods of using GDNF as a neuroprotective agent |
US5731284A (en) * | 1995-09-28 | 1998-03-24 | Amgen Inc. | Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product |
US6184200B1 (en) * | 1995-09-28 | 2001-02-06 | Amgen Inc. | Truncated glial cell line-derived neurotrophic factor |
US5837681A (en) * | 1996-02-23 | 1998-11-17 | Amgen Inc. | Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product |
US5929041A (en) * | 1996-02-23 | 1999-07-27 | Amgen Inc. | Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product |
US5741778A (en) * | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
FR2753379B1 (fr) * | 1996-09-13 | 1998-10-30 | Rhone Poulenc Rorer Sa | Methode de traitement de la sclerose laterale amyotrophique |
AU6975198A (en) * | 1997-04-15 | 1998-11-11 | University Of Medicine And Dentistry Of New Jersey | Cdna for human gdnf and promoter therefor which allows regulated and constitutive expression |
US6043221A (en) * | 1997-07-30 | 2000-03-28 | Amgen Inc. | Method for preventing and treating hearing loss using a neuturin protein product |
US6277820B1 (en) | 1998-04-09 | 2001-08-21 | Genentech, Inc. | Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells |
DE19816186A1 (de) * | 1998-04-14 | 1999-10-21 | Univ Muenchen L Maximilians | GDNF-kodierende DNA, Teile davon und GDNF-Varianten |
IL146694A (en) | 2001-11-22 | 2010-12-30 | Biomas Ltd | Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament |
EP1478236B1 (en) | 2001-12-21 | 2009-02-11 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery to motor neurons |
AU2004304716B2 (en) * | 2003-12-18 | 2010-05-27 | Biomas Ltd. | Tellurium derivatives for prevention and treatment of neurodegenerative processes |
PL2019683T5 (pl) * | 2006-04-25 | 2022-12-05 | The Regents Of The University Of California | Podawanie czynników wzrostu do leczenia zaburzeń OUN |
EP2023949A4 (en) * | 2006-04-26 | 2009-08-26 | Univ California | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NEUROTHERAPY OF HIGH MOLECULAR WEIGHT ENHANCED BY CONVECTION |
US8124749B2 (en) | 2007-06-12 | 2012-02-28 | Case Western Reserve University | Targeted cell death |
CN102159713A (zh) | 2008-05-20 | 2011-08-17 | Eos神经科学公司 | 用于递送光敏蛋白的载体和使用方法 |
US20140259192A1 (en) | 2011-07-12 | 2014-09-11 | Sanofi | Transgenic animal comprising a deletion or functional deletion of the 3'utr of an endogenous gene |
EP2968462B1 (en) | 2013-03-15 | 2020-12-23 | The Jackson Laboratory | Methods for promoting wound healing and hair growth |
DK3764961T3 (da) | 2018-03-15 | 2024-04-22 | Coloplast As | Apparat og fremgangsmåder til at navigere en bruger af et stomiapparat til et omklædningsrum |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
FR2688514A1 (fr) * | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
ATE404683T1 (de) * | 1992-09-25 | 2008-08-15 | Aventis Pharma Sa | Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn |
FR2702152B1 (fr) * | 1993-03-03 | 1995-05-24 | Inst Nat Sante Rech Med | Virus recombinants et leur utilisation en thérapie génique. |
-
1994
- 1994-03-25 FR FR9403542A patent/FR2717824B1/fr not_active Expired - Lifetime
-
1995
- 1995-03-23 IL IL11310995A patent/IL113109A0/xx unknown
- 1995-03-23 DE DE69535155T patent/DE69535155T2/de not_active Expired - Lifetime
- 1995-03-23 WO PCT/FR1995/000356 patent/WO1995026408A1/fr active Search and Examination
- 1995-03-23 MX MX9604024A patent/MX9604024A/es unknown
- 1995-03-23 KR KR1019960705454A patent/KR100403707B1/ko not_active IP Right Cessation
- 1995-03-23 US US08/716,326 patent/US6245330B1/en not_active Expired - Lifetime
- 1995-03-23 JP JP7524993A patent/JPH09510620A/ja active Pending
- 1995-03-23 AT AT95914402T patent/ATE335832T1/de not_active IP Right Cessation
- 1995-03-23 CA CA002184841A patent/CA2184841C/fr not_active Expired - Lifetime
- 1995-03-23 EP EP95914402A patent/EP0752004B1/fr not_active Expired - Lifetime
- 1995-03-23 AU AU21411/95A patent/AU704910B2/en not_active Expired
- 1995-03-24 ZA ZA952433A patent/ZA952433B/xx unknown
-
1996
- 1996-09-24 FI FI963805A patent/FI963805A/fi not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL113109A0 (en) | 1995-06-29 |
EP0752004A1 (fr) | 1997-01-08 |
KR970702373A (ko) | 1997-05-13 |
DE69535155T2 (de) | 2007-06-28 |
US6245330B1 (en) | 2001-06-12 |
ATE335832T1 (de) | 2006-09-15 |
ZA952433B (en) | 1996-01-15 |
EP0752004B1 (fr) | 2006-08-09 |
MX9604024A (es) | 1997-09-30 |
WO1995026408A1 (fr) | 1995-10-05 |
FI963805A (fi) | 1996-09-24 |
KR100403707B1 (ko) | 2004-02-11 |
CA2184841A1 (fr) | 1995-10-05 |
CA2184841C (fr) | 2009-08-18 |
DE69535155D1 (de) | 2006-09-21 |
AU2141195A (en) | 1995-10-17 |
AU704910B2 (en) | 1999-05-06 |
FR2717824B1 (fr) | 1996-04-26 |
JPH09510620A (ja) | 1997-10-28 |
FR2717824A1 (fr) | 1995-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI963805A0 (fi) | Hermotukisoluista peräisin olevaa neurotrofista tekijää (GDNF) koodaavat yhdistelmä-DNA-tekniset adenovirukset | |
Wang et al. | Tendon healing in vitro: genetic modification of tenocytes with exogenous PDGF gene and promotion of collagen gene expression | |
Korte et al. | Virus-mediated gene transfer into hippocampal CA1 region restores long-term potentiation in brain-derived neurotrophic factor mutant mice. | |
Akimoto et al. | Adenovirally expressed basic fibroblast growth factor rescues photoreceptor cells in RCS rats. | |
Barkats et al. | Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases | |
Leslie et al. | Nerve growth factor contributes to the up-regulation of growth-associated protein 43 and preprotachykinin A messenger RNAs in primary sensory neurons following peripheral inflammation | |
Cantini et al. | Macrophages regulate proliferation and differentiation of satellite cells | |
Ebendal | Function and evolution in the NGF family and its receptors | |
Ono et al. | Brain-derived neurotrophic factor reduces blood glucose level in obese diabetic mice but not in normal mice | |
Ebendal | NGF in CNS: experimental data and clinical implications | |
JP2702811B2 (ja) | 改変型毛様体神経栄養因子 | |
Ernfors et al. | Developmental and regional expression of basic fibroblast growth factor mRNA in the rat central nervous system | |
Matsuda et al. | Effect of basic fibroblast growth factor on neurons cultured from various regions of postnatal rat brain | |
Haase et al. | Adenovirus-mediated transfer of the neurotrophin-3 gene into skeletal muscle of pmn mice: therapeutic effects and mechanisms of action | |
Davies | Paracrine and autocrine actions of neurotrophic factors | |
CA2243261A1 (en) | Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions | |
WO1997026337B1 (en) | Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions | |
Tuszynski et al. | Central infusions of brain-derived neurotrophic factor and neurotrophin-45, but not nerve growth factor and neurotrophin-3, prevent loss of the cholinergic phenotype in injured adult motor neurons | |
EP1674108A3 (en) | Osteoporosis treatment | |
CA2315277A1 (en) | Pharmaceutical compositions containing the long pentraxin ptx3 | |
Houlgatte et al. | Levels of nerve growth factor secreted by rat primary fibroblasts and iris transplants are influenced by serum and glucocorticoids | |
Robert et al. | Adenovirus-mediated transfer of a functional GAD gene into nerve cells: potential for the treatment of neurological diseases | |
CN1155706C (zh) | 肌萎缩性侧索硬化的治疗方法 | |
Horellou et al. | In VivoAdenovirus-Mediated Gene Transfer for Parkinson's Disease | |
Noel et al. | The stimulation of fibroblasts collagen synthesis by neoplastic cells is modulated by the extracellular matrix |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MA | Patent expired |